Hypercapnia

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

Retrieved on: 
fredag, mars 15, 2024
Hypercapnia, Respironics, VAPO, Business, Patient, Mechanical ventilation, Spirometry, Business development, Quality of life, Respiratory disease, OTCQX, NIV, COPD, FDA, HME, Hospital

EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Key Points: 
  • EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
  • Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company's commitment to improving the lives of hypercapnic patients in the home.
  • "(1)
    The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th.
  • Joe Army, President and CEO of Vapotherm, underscored the significance of the solution, stating, "Vapotherm is committed to supporting patients both in and out of the hospital.

Etiometry Unveils 2024 Priorities and Celebrates Milestones: Clinical Outcomes Data Show Significant Reductions in Length of Stay (LOS)

Retrieved on: 
tisdag, januari 30, 2024
Software, Practice Management, General Health, Health, Data Management, Hospitals, Health Technology, Technology, Carbon, Partnership, Abstract, Cardiology, ICU, Attention, EHR, IDO2, Hypercapnia, Hospice and palliative medicine, Research, Nursing care plan, Hospital, NICU, Analytics, Patient, Safety, Data science, FDA, SOC, Automation, QIA, Radiometer, Carbon dioxide, Algorithm, Purchasing, Length of stay, Quality, System, Pharmaceutical industry

A multicenter randomized clinical trial showed a reduction in time patients were on vasoactive medication by 18%.

Key Points: 
  • A multicenter randomized clinical trial showed a reduction in time patients were on vasoactive medication by 18%.
  • This was the first study to explore the use of algorithms in the safe de-escalation of care.
  • "The clinical outcomes data tell a compelling story of how Etiometry's platform is reshaping the landscape of critical care.
  • As the evidence highlighting the clinical efficacy of the Etiometry platform continues to grow, so does the attention from industry stakeholders.

Etiometry Gains FDA Clearance of AI-Based Algorithm that Alerts Risk of Hypercapnia for Neonates in Critical Care

Retrieved on: 
tisdag, augusti 1, 2023
Cardiology, Data Management, Technology, FDA, Other Health, Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Hospitals, Abstract, NICU, PCO2, Multimedia, Hypercapnia, Annals of Pediatric Cardiology, Congress, Food and Drug Administration Amendments Act of 2007, Patient, Risk, Picus, Digital, Nursing care plan, ICU, Intensive care unit, Environment, Food, Medical device, Nursing

View the full release here: https://www.businesswire.com/news/home/20230801099358/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230801099358/en/
    Etiometry’s IVCO2 Index™ alerts risk of hypercapnia in critical care patients.
  • This algorithm was recently FDA cleared for use on neonates.
  • Vigilant monitoring for hypercapnia is critical for maximizing neurodevelopmental outcomes and preventing complications in these fragile patients.
  • “The IVCO2 Index™ is a first-of-its-kind algorithm that increases the ability to detect hypercapnia risk without needing additional hardware attached to these fragile patients,” said Dimitar Baronov, CTO of Etiometry.

Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia

Retrieved on: 
tisdag, mars 21, 2023
Technology, FDA, Clinical Trials, Health Technology, Software, Health, General Health, Data Management, Artificial Intelligence, Probability, Pediatrics, CE marking, Physiology, PCO2, Multimedia, Hypercapnia, Carbon, Ventilation, Vital signs, Patient, Length of stay, Mercury (element), CO2, Nursing care plan, Health Canada, Safety, Nursing, Medical device

Etiometry , the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2Index™ for adult populations, which allows clinicians to visualize inadequate ventilation of carbon dioxide with other contextual data from the Etiometry Platform to help inform intervention decisions and get ahead of patient deterioration.

Key Points: 
  • Etiometry , the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2Index™ for adult populations, which allows clinicians to visualize inadequate ventilation of carbon dioxide with other contextual data from the Etiometry Platform to help inform intervention decisions and get ahead of patient deterioration.
  • The IVCO2 Index was first FDA-cleared for pediatric use in 2019 and now carries CE Mark and Health Canada licenses for both pediatric and adult use.
  • View the full release here: https://www.businesswire.com/news/home/20230321005034/en/
    Etiometry’s IVCO2 Index™ - derived using key vital signs and laboratory results collected by the Etiometry Platform - determines the likelihood of inadequate carbon dioxide ventilation.
  • “We are serious in our pursuit to expand authorizations of all four of our current risk indices,” said Shane Cooke, CEO of Etiometry.

Spaulding Clinical and FDA Study Contributing to Efforts to Address Opioid Crisis

Retrieved on: 
onsdag, januari 25, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Human, American Medical Association, Paroxetine, Oxycodone, Hypercapnia, Carbon, Depression, Clinical trial, Food, Risk, Anxiety, Death, SSRI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hypoventilation, Ventilation, Pharmaceutical industry, Medical device

Spaulding Clinical , a full-service Phase I clinical service provider, worked with the U.S. Food and Drug Administration (FDA) to conduct a clinical trial as a part of the FDA’s proactive effort to address the opioid crisis and reduce opioid overdoses and deaths.

Key Points: 
  • Spaulding Clinical , a full-service Phase I clinical service provider, worked with the U.S. Food and Drug Administration (FDA) to conduct a clinical trial as a part of the FDA’s proactive effort to address the opioid crisis and reduce opioid overdoses and deaths.
  • This trial evaluated whether two common psychotropic drugs would further decrease ventilation when combined with an opioid compared to an opioid alone.
  • Opioids can decrease ventilatory response to hypercapnia, or excessive carbon dioxide in the bloodstream, which can cause severe respiratory depression or death.
  • Since 2016, the FDA has required boxed warnings for both benzodiazepine and opioid products about increased respiratory depression risk with simultaneous use.

Vapotherm to Report Third Quarter 2022 Financial Results

Retrieved on: 
onsdag, oktober 26, 2022
Health, Medical Supplies, Other Health, Medical Devices, U.S. Securities and Exchange Commission, Breathe Me, Telephone, Investor relations, Regulation Fair Disclosure, Investor, NYSE, Patient, Security (finance), Company, VAPO, Hypercapnia, Hypoxemia, Gas, Regulation, Pharmaceutical industry, Vapotherm

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022.
  • ET to discuss the financial results and recent business developments.
  • To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events .
  • The webcast replay will be available on the Vapotherm website for 90 days following completion of the call.

Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice

Retrieved on: 
måndag, oktober 3, 2022
General Health, Health, Other Health, Medical Devices, Regulation, Second Amendment to the United States Constitution, Achievement, Breathe Me, Hypercapnia, Regulation Fair Disclosure, Security, Compliance, Food, U.S. Securities and Exchange Commission, VAPO, Private Securities Litigation Reform Act, Hypoxemia, Patent, Failure, COVID-19, District of Columbia Voting Rights Amendment, Finance Secretary (India), Food and Drug Administration, Notice, Gas, LIBOR, NYSE, Plan, Security (finance), Patient, Risk, Investor relations, Term, Security agreement, Company, Vapotherm

In accordance with the NYSE rules, the Company intends to notify the NYSE within 10 business days of receipt of the Notice that the Company intends to cure the deficiency.

Key Points: 
  • In accordance with the NYSE rules, the Company intends to notify the NYSE within 10 business days of receipt of the Notice that the Company intends to cure the deficiency.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.
  • This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties, including its intent to regain compliance with the NYSE continued listing standards.

Global Extracorporeal CO2 Removal Devices Market Size, Share & Trends Analysis 2021-2028 by Application (ARDS, COPD), Access (Venovenous, Arteriovenous), & End Use (ASCs, Clinics) - ResearchAndMarkets.com

Retrieved on: 
fredag, december 10, 2021
Managed Care, Hospitals, Health, Medical Devices, Hypercapnia, Ventilation, Prevalence, Patient, Asthma, CAGR, USD, Globe, Hospital, CO2, Chronic obstructive pulmonary disease, Adoption, COPD, Canadian Lung Association, Pharmaceutical industry, Medical device

The "Extracorporeal CO2 Removal Devices Market Size, Share & Trends Analysis Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Extracorporeal CO2 Removal Devices Market Size, Share & Trends Analysis Report" has been added to ResearchAndMarkets.com's offering.
  • Extracorporeal CO2 removal devices are considered to be an efficient therapy for patients suffering from hypercapnia respiratory failure and may allow clinicians as well as healthcare professionals to improve lung-protective ventilation.
  • These devices can remove adequate CO2 to allow a 50% reduction in alveolar minute ventilation resulting in a substantial reduction in PaCO2.
  • Extracorporeal CO2 machines held the largest revenue share of the global market in 2020 owing to the availability of a wide range of devices.

FDA Grants the Hemolung® De Novo Clearance

Retrieved on: 
måndag, november 15, 2021
Health, FDA, Medical Devices, Other Health, General Health, Clinical Trials, Biotechnology, GMP, University, ICU, Carbon dioxide, Hypercapnia, MD, COPD, CO2, CEO, Doctor of Philosophy, Technology, Failure, Food, De novo, ECMO, The Act, ECCO2R, PCO2, COVID, COVID-19, Chronic obstructive pulmonary disease, Multimedia, Emergency Use Authorization, Food and Drug Administration Amendments Act of 2007, Respiratory failure, Mercer University Health Sciences Center, Extracorporeal, Ventilation, Philips, Hospital, Partial pressure, Company, Failure rate, Nursing, EUA, COVID 19, Physician, Louisiana, Patient, Risk, FDA, Dietary supplement, Medical device, Pharmaceutical industry

The Hemolung System is the first and only ECCO2R device cleared by the FDA.

Key Points: 
  • The Hemolung System is the first and only ECCO2R device cleared by the FDA.
  • In order to demonstrate benefit over risk, ALung submitted data to FDA from over 1,000 Hemolung patient treatments on clinical safety and over 230 Hemolung patient treatments on clinical performance outcomes.
  • This clinical data along with all of our pre-clinical data demonstrated to the FDA that the clinical benefits of the Hemolung for ECCO2R therapy has been substantiated.
  • For more information on the use of the Hemolung RAS for COVID-19 patients, please visit www.alung.com/covid-19
    *The Hemolung RAS has been authorized for the above emergency use by FDA under an EUA.

Extracorporeal CO2 Removal Devices Market Worth $118.6 Million By 2028: Grand View Research, Inc.

Retrieved on: 
måndag, oktober 11, 2021
Hypercapnia, USD, EAP, SAN, CAGR, Canadian Lung Association, RAS, FDA, Chronic obstructive pulmonary disease, Ventilation, Prevalence, Globe, CO2, COPD, Asthma, 3D ultrasound, Revenue, Clinic, Patient, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Oct. 11, 2021 /PRNewswire/ --The global extracorporeal CO2 removal devices market size is estimated to reach USD 118.64 million by 2028, registering a CAGR of 5.27% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Oct. 11, 2021 /PRNewswire/ --The global extracorporeal CO2 removal devices market size is estimated to reach USD 118.64 million by 2028, registering a CAGR of 5.27% over the forecast period, according to a new report by Grand View Research, Inc.
  • These devices can remove adequate CO2 to allow a 50% reduction in alveolar minute ventilation resulting in a substantial reduction in PaCO2.
  • Extracorporeal CO2 removal devices are effective, safe, and feasible.
  • Grand View Research has segmented the global extracorporeal CO2 removal devices market on the basis of product, application, access, end use, and region:
    Extracorporeal CO2 Removal Devices Product Outlook (Revenue, USD Million, 2016 - 2028)